How much do Hemlibra sales generate, and who buys it?
Hemlibra (emicizumab) is a hemophilia A treatment used to prevent bleeding by replacing or mimicking factor VIII function. Sales figures depend on the country, reporting period, and whether you mean unit sales (doses) or revenue.
If you’re looking for a specific number (for example, “Hemlibra sales in 2023” or “Hemlibra annual revenue”), the exact figure will change based on the data source (company earnings, market-research estimates, or payer/registry reporting). You’ll also see different reporting terms such as “global sales,” “net sales,” or “revenue,” which can affect comparability.
What drives Hemlibra sales growth or decline?
Hemlibra sales typically move with:
- Uptake in eligible patients with hemophilia A, especially those with inhibitors.
- Pricing and reimbursement in different regions.
- Competitive dynamics in prophylaxis for hemophilia A (including other factor VIII and non-factor therapies).
- Changes in treatment patterns (switching from on-demand therapy or factor prophylaxis to emicizumab prophylaxis).
- Manufacturer and distribution capacity and any supply disruptions.
What are the main revenue components behind Hemlibra?
Hemlibra revenue is generally tied to:
- Dose volume (how many patients stay on therapy and for how long).
- Concentration/formulation used and local labeling dosing.
- Country mix (higher or lower net prices after rebates/discounts).
How can you find the latest Hemlibra sales numbers?
Most reliable sources for “current Hemlibra sales” are:
- Roche/Genentech quarterly and annual results (net sales by product line/therapeutic area when disclosed).
- Investor presentations and earnings call transcripts (often include trend commentary).
- Reputable market-research trackers (useful for estimates, but methodology varies).
If you tell me the year (or quarter) and the region you mean (global vs US vs EU vs specific country), I can point you to the correct published figures to use and how to interpret them.